Recent studies from Feinberg scientists have uncovered new insights into these disorders, elucidating the mechanisms behind Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis, or ALS.
Author: Olivia Dimmer
As GLP-1 receptor agonist medications like semaglutide have been shown to be effective at helping patients lose weight, scientists are now asking, whether they can treat other conditions where obesity is a risk factor. Most recently, initial studies have shown that they can reduce the risk of cardiovascular disease by reducing overall body weight.
In the last several years, anti-obesity medications have made an impression through wide media coverage and interest in their effectiveness. Feinberg investigators have been leading research on these drugs for the treatment of obesity and advocating for access to these medications for the patients who need it most.
Mary Kwasny, ScD, professor of Preventive Medicine in the Division of Biostatistics, has received the American Statistical Association’s (ASA) Founders Award, the highest award the organization bestows for distinguished service.
The Breakthroughs podcast released 19 episodes in 2023 on topics ranging from implementation science and ChatGPT to new insights in dopamine and AI in healthcare. The top three most downloaded episodes this year were on varying topics including exercise and Parkinson’s disease, food allergies and recent discoveries about mitochondria.
Since the COVID-19 pandemic thrust many providers into telehealth appointments, scientists have been asking questions about the benefits and concerns of telehealth. While telehealth was in use and gathering interest prior to the pandemic, the need for it accelerated during a time when people were encouraged to stay home.
Twelve Feinberg faculty members were named to the 2023 “Highly Cited Researchers” list, published by Clarivate Analytics. The annual list identifies investigators who have demonstrated significant influence in their field through the publication of highly cited publications during the last decade.
Though treatments for allergies have historically been slow-going, recent research by Feinberg investigators has provided new hope for the future of allergy management.
Sex is a major determinant in disease prevalence and treatment response, caused by a vast number of genetic differences between men and women. However, the inclusion of both sexes in clinical and scientific research had not been mandated by federal law until nearly the turn of the century.
In 2022, Feinberg established research into social determinants of health as a priority. To better understand the impact of social determinants of health, Feinberg investigators have been leading studies that provide new insights into how a person’s neighborhood can positively or negatively affect their health.